上市公司資料
 
無錫藥明康德新藥開發股份有限公司 股票代號:  02359
WUXI APPTEC CO., LTD. 集團網址: http://www.wuxiapptec.com.cn
損益表
  2023/12
RMB(K$)
變動 2022/12
RMB(K$)
2021/12
RMB(K$)
營業額40,340,8072.505%39,354,77822,902,385
經營溢利/(虧損)12,997,16221.870%10,664,7486,132,900
特殊項目--------
攤佔聯營公司及共同控制公司溢利/(虧損)(67,560)--(46,271)(117,291)
稅前溢利/(虧損)12,929,60221.765%10,618,4776,015,609
稅項(2,131,731)--(1,715,866)(879,662)
少數股東權益(107,718)--(88,898)(38,792)
股東應佔溢利/(虧損)10,690,15321.290%8,813,7135,097,155
 
淨利息收入/(支出)250,889709.084%31,00963,360
折舊與攤銷2,511,85131.053%1,916,6651,479,943
董事酬金137,5337.977%127,37270,016
 
每股盈利/(虧損)(仙)364.00020.930%301.000175.000
每股派息(仙)98.97410.875%89.26651.740
 
派息比率(%)27.191%--29.656%29.566%
每股帳面資產淨值($)18.56717.983%15.73713.022
主要財務比率
  2023/12
RMB(K$)
變動 2022/12
RMB(K$)
2021/12
RMB(K$)
經營邊際利潤率(%)32.218%--27.099%26.778%
利息盈利率(x)67.792--67.43347.875
資產回報率(%)15.453%--14.712%10.052%
股東資金回報率(%)21.020%--20.718%14.361%

 

Copyright © 2025 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.